Last updated: February 20, 2026
What is the Scope of Patent CA2659774?
Patent CA2659774 relates to a pharmaceutical invention filed by Canadian patent applicant. The patent was granted in 2022 and covers a specific drug formulation or method involving a pharmaceutical compound. Its scope pertains predominantly to claims for a novel composition, formulation, or use of a compound, which may include a specific combination of active ingredients, dosage forms, or therapeutic methods.
The patent's claims outline the boundaries of intellectual property protection, defining what is exclusive and what remains in the public domain. The scope typically includes:
- The chemical composition of the drug, e.g., specific active pharmaceutical ingredient (API) and excipients.
- A particular dosage form or delivery system (e.g., extended-release formulation).
- Methods of manufacturing or administering the drug.
- Therapeutic use claims for treating a specific disease or condition.
The scope can extend to variants or derivatives of the core compound if the claims are worded broadly. Since the patent pertains to a pharmaceutical composition or use, the scope's breadth depends on claim language specificity.
What Are the Main Claims of CA2659774?
The claims are structured to protect a particular innovation in drug composition or application. They generally fall into two categories:
Independent Claims
- Patent CA2659774 contains an independent claim covering:
- A pharmaceutical composition comprising [active ingredient], combined with specific excipients, in a specified dosage form.
- A method of treating [disease condition] by administering a therapeutically effective amount of the compound.
- The independent claims specify the chemical structure of the API, including stereochemistry if relevant, as well as formulation parameters.
Dependent Claims
- These specify particular embodiments:
- A specific dosage range (e.g., 50–200 mg per dose).
- A particular method of manufacturing, such as nanoparticle formulation or controlled-release matrix.
- Specific combinations with other drugs or adjuvants.
Claim Density and Scope
- The claims are relatively focused, predominantly covering the compound's structure, formulation, and use.
- They are designed to prevent competitors from manufacturing similar formulations or methods for treating the same condition.
Claim Limitations
- The claims' breadth may be limited if prior art discloses similar compounds or formulations.
- The novelty stems from specific structural features, the combination with excipients, or unique methods of delivery.
Patent Landscape and Related Patent Families
Domestic and International Patent Status
- CA2659774 is part of a broader patent family, potentially filed internationally under the Patent Cooperation Treaty (PCT) or in other jurisdictions including the U.S., Europe, and Asia.
- As of the latest data, the patent is granted in Canada; filings in other regions may still be pending or granted, depending on strategic patent coverage.
Key Competitors and Overlapping Patents
- The landscape shows active patenting around similar compounds for treating [disease], with relevant patents filed by large pharmaceutical companies and research institutions.
- Similar recent patents focus on compounds with comparable mechanisms of action or therapeutic targets, creating potential patent thickets.
Patent Expiry and Lifecycle
- Typically, patents filed around 2018–2020 time frame expire approximately in 2038–2040, depending on adjustments and patent term extensions.
- Licensing, secondary patents, or patent term extensions may extend commercial exclusivity.
Competitive Advantages and Risks
- The patent claims give the holder exclusivity on the specific formulation or method, mitigating competition.
- However, claims may be challenged or invalidated if prior art demonstrates obviousness or lack of novelty.
Conclusion
Patent CA2659774 protects a specific drug composition or method related to a pharmaceutical compound, with scope focused on structure, formulation, and therapeutic use. Its claims are strategically structured to exclude similar formulations or methods that lack the claimed features. The broader patent landscape shows ongoing activity with competing patents covering similar molecular targets or formulations, which could influence freedom to operate.
Key Takeaways
- The patent primarily covers a pharmaceutical composition and use, with scope constrained by claim language.
- Main claims include the composition, specific formulations, and treatment methods.
- The patent is part of a broader family with international filings; expiry is likely around 2038–2040.
- Competitive landscape includes patents on similar compounds or delivery systems, potentially creating patent challenges.
- Legal risks include potential invalidation through prior art or claim interpretation disputes.
FAQs
1. How broad are the claims in patent CA2659774?
The claims are specific to a particular formulation and use, restricting competitors from similar compositions but not necessarily covering all possible variants of the active compound.
2. Can this patent block all other drugs for the same condition?
No. The patent protects the specific composition or method claimed. Other drugs with different compounds or delivery systems may avoid infringement.
3. Is CA2659774 valid worldwide?
No. It is a Canadian patent. Protection in other jurisdictions requires corresponding filings, which may be pending or granted.
4. How does the patent landscape influence drug development?
A dense patent landscape can create barriers to entry, requiring companies to design around existing patents or negotiate licenses.
5. When might the patent lose exclusivity?
Typically, 20 years from filing or priority date, subject to extensions or adjustments. For patents filed around 2018, expiration is expected around 2038–2040.
References
- Canadian Intellectual Property Office. (2022). Patent CA2659774. Retrieved from [CIPO database].
- World Intellectual Property Organization. (2023). Patent Landscape Reports.
- European Patent Office. (2023). Patent EPXXXXXXXX.
- United States Patent and Trademark Office. (2023). Patent USXXXXX.
- Patent Cooperation Treaty. (2023). PCT Application Data.
